Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.43 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.43 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2045490 | 0.95 | MEN1 (0.58) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL11512989 | 0.93 | MEN1 (0.56) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL11515285 | 0.93 | MEN1 (0.56) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL366283 | 0.90 | CYP2C19 (0.62) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL9451018 | 0.87 | MEN1 (0.41) | CYP2C19MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL23483030 | 0.87 | MEN1 (0.45) | CYP2C19MEN1KMT2A | |
| SCHEMBL24109360 | 0.87 | MEN1 (0.45) | CYP2C19MEN1KMT2A | |
| Biphenyl SCHEMBL28725381 | 0.83 | MEN1 (0.56) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL9778742 | 0.82 | KDM1A (0.49) | CYP2C19MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL5946282 | 0.79 | CYP2C19 (0.62) | CYP2C19MEN1KMT2ATSHRKCNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899122-A | Cyclobutylmethyl and phenyl substituted curcumin derivative and preparation method and application thereof | 常州大学 | 2025-04-29 | — | — | CN | claimed |
| EP-3365418-A2 | PARTICLES FOR MALODOR REDUCTION | The Procter and Gamble Company (US) | 2018-08-29 | — | — | EP | claimed |
| WO-2017070131-A2 | PARTICLES FOR MALODOR REDUCTION | THE PROCTER & GAMBLE COMPANY (US) | 2017-04-27 | — | — | WO | claimed |
| CN-106521936-A | Quick penetrating agent for fabric | 无锡市华诚印染剂厂 | 2017-03-22 | — | — | CN | claimed |
| EP-0820454-B1 | ANELLATED BETA-CARBOLINES | SCHERING AG (DE) | 2002-07-24 | — | — | EP | claimed |
| US-6118422-A | Light scattering type liquid crystal display device, and method for driving it | CHISSO CORPORATION (JP) | 2000-09-12 | — | — | US | claimed |
| US-5350750-A | Tranquilizers, memory enhancement | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-09-27 | — | — | US | claimed |
| JP-1139576-A | — | — | None | — | — | JP | disclosed |
| EP-4036149-B1 | HETEROBIFUNCTIONAL MONODISPERSED POLYETHYLENE GLYCOL HAVING PEPTIDE LINKER | NOF CORP (JP) | 2026-04-29 | — | — | EP | disclosed |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | SYMRISE AG (DE) | 2026-04-09 | — | — | US | disclosed |
| US-20250326984-A1 | FRAGRANCES WITH CYCLOPROPYL STRUCTURE | SYMRISE AG (DE) | 2025-10-23 | — | — | US | disclosed |
| US-20250205143-A1 | ADDITIVE FOR SUNSCREENS | SYMRISE AG (DE) | 2025-06-26 | — | — | US | disclosed |
| CN-119899122-A | Cyclobutylmethyl and phenyl substituted curcumin derivative and preparation method and application thereof | 常州大学 | 2025-04-29 | — | — | CN | disclosed |
| US-4193901-A | WITH A MIXTURE OF A SULFUR TRIOXIDE-LEWIS BASE COMPLEX AND A CARBOXYLIC ANHYDRIDE OR ACYL HALIDE | EXXON RESEARCH & ENGINEERING CO. (US) | 1980-03-18 | — | — | US | disclosed |
| US-4190668-A | Stabilized aqueous amide antimicrobial composition | THE DOW CHEMICAL COMPANY (US) | 1980-02-26 | — | — | US | disclosed |
| US-4162241-A | NEUTRALIZED SULFONATED BUTYL RUBBER OR DIENE-ETHYLENE-PROPYLENE TERPOLYMER | EXXON RESEARCH & ENGINEERING CO. (US) | 1979-07-24 | — | — | US | disclosed |
| EP-0002358-A2 | Process for forming a zinc neutralised sulphonated elastomeric polymer and composition thereof | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1979-06-13 | — | — | EP | disclosed |
| EP-0002354-A1 | A process for sulphonating elastomeric polymers | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1979-06-13 | — | — | EP | disclosed |
| EP-0002353-A1 | A process for forming a polymer that contains metalsulphonate | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1979-06-13 | — | — | EP | disclosed |
| US-4105647-A | SOLUTION POLYMERIZATION USING A FRIEDEL-CRAFTS OF ZIEGLER-TYPE CATALYST | EXXON RESEARCH & ENGINEERING CO. (US) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326984-A1 | FRAGRANCES WITH CYCLOPROPYL STRUCTURE | CBR3, CNR1, CBR1 | CYP2C19 1172/4885MEN1 3001/4885KMT2A 3793/4885 |
| US-20250205143-A1 | ADDITIVE FOR SUNSCREENS | CUTA, BRCA1, SUN2 | CYP2C19 1239/4885MEN1 909/4885KMT2A 1019/4885 |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | PTGS2, PTGES2, PTGS1 | CYP2C19 743/4885MEN1 2489/4885KMT2A 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.